Protracted Benzodiazepine Withdrawal:
Why Symptoms Can Persist Without Ongoing Brain Injury

Persistent symptoms after benzodiazepine withdrawal—often referred to as protracted withdrawal or post-acute withdrawal syndrome (PAWS)—can be difficult to understand, both for patients and clinicians.

 

In some individuals, symptoms extend far beyond the expected acute withdrawal period—lasting months or, in some cases, years.

​

These symptoms often include anxiety and insomnia, along with internal restlessness, sensory sensitivity, gastrointestinal symptoms, autonomic instability, cognitive changes, and bodily sensations that can shift over time.

​

Because of their intensity and duration, many people describe this experience using terms such as “benzo brain injury,” “nervous system damage,” or “brain injury.”

​

These descriptions reflect something real—the severity and persistence of the symptoms—but they do not necessarily reflect the underlying biology of the nervous system.​

​

​

What Is Protracted Benzodiazepine Withdrawal?​

​

Benzodiazepine withdrawal unfolds over time rather than as a single event. Symptoms may begin within hours to days after dose reduction or discontinuation, depending on the medication’s half-life.

​

Shorter-acting agents (such as alprazolam) are associated with earlier onset, while longer-acting agents (such as diazepam) are associated with later onset.

​

The acute withdrawal phase is generally considered to last 1 to 4 weeks.

​

When symptoms persist well beyond the acute withdrawal period, they are often described as protracted benzodiazepine withdrawal or, more broadly, post-acute withdrawal syndrome (PAWS).

​

In this prolonged phase, symptoms may persist for months or longer and often fluctuate.

​

Common symptoms include:

• anxiety, panic attacks, and insomnia

• sensitivity to sound, light, foods, and supplements

• autonomic instability (heart rate, breathing, temperature regulation)

• cognitive symptoms (e.g., brain fog or “brain zaps”)

• internal restlessness or akathisia

​

Because of their intensity and persistence, these symptoms are often interpreted as evidence of injury. However, this interpretation does not necessarily reflect the underlying biology.​

​

​

Why Benzodiazepine Withdrawal Symptoms Can Persist​

​

A common conclusion is: “If symptoms are this severe, last this long, and I’m not getting any relief, something must be damaged.”

​

In many areas of medicine, persistent symptoms are associated with structural injury, but this relationship does not always hold.

​

This raises a key question: why do symptoms persist, even in the absence of clear structural injury?

​

Symptoms can persist because they are not a direct measure of tissue damage. They arise from how the brain and body generate, amplify, and interpret signals over time.​

​

​​

A Mechanism-Based Model of Symptom Generation and Persistence​

​

Symptoms can be understood as emerging from brain–body signaling through three interacting processes:

• signal generation

• signal amplification

• signal interpretation

​

These same processes not only generate symptoms—they can also remain dysregulated over time, allowing symptoms to persist even in the absence of structural injury.

​​​

​​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​​

​​

​​

​​​Symptoms arise from signal generation, amplification, and interpretation across interacting brain–body systems. When these processes remain dysregulated, symptoms can persist over time without requiring ongoing structural injury.

​

These processes determine not only whether a signal is generated, but whether it is amplified, prioritized, and ultimately experienced as a symptom.

 

During and after benzodiazepine withdrawal, several changes in nervous system function can occur as GABAergic inhibitory tone decreases:

• reduced inhibitory stability

• increased neural sensitivity (higher gain)

• increased stress system activation

• altered autonomic regulation

 

Together, these changes lower the threshold for signal generation and increase the likelihood that signals will be amplified, brought into awareness, and experienced as symptoms.

​

The intensity of symptoms reflects how strongly signals are amplified and prioritized—not necessarily the presence of structural damage. A sensitized nervous system can produce symptoms that feel extreme, even in the absence of fixed injury.

​

Symptoms can persist not because new problems are developing, but because the system’s ability to regulate, dampen, and return to baseline remains impaired.

​

In some cases, these processes can become self-reinforcing, sustaining symptoms over time. They do not always recalibrate quickly. Changes in inhibitory signaling, stress-system activation, and autonomic regulation can take time to settle, allowing symptoms to persist for months or longer even in the absence of ongoing injury.

 

​

A Systems-Level Organization of Symptoms​

​

The processes described above do not occur within a single system. They are distributed across interacting regulatory domains, including stress and threat signaling, neural amplification, autonomic regulation, motor output, and sensory and immune signaling.

​

In clinical practice, these domains can be organized using a systems framework—such as the Five-Axis Stress Biology Framework™—which maps how different regulatory networks contribute to symptom generation and persistence.

​

This type of organization helps explain why symptoms can involve multiple systems, change in intensity, and present in different forms over time.

​

Symptoms, therefore, often reflect combined activity across systems, rather than a single localized problem.

 

​​

What Brain Imaging Shows in Benzodiazepine Use and Withdrawal​

​

Persistent symptoms after benzodiazepine withdrawal have been described for decades, including in widely referenced clinical resources such as the Ashton Manual, which outlines both acute and prolonged withdrawal patterns.

​

In that framework, symptoms were understood as arising from changes in nervous system function—particularly adaptations in GABA signaling—rather than from structural brain injury.

Standard structural imaging, such as MRI or CT scans, has not consistently demonstrated abnormalities that account for persistent withdrawal symptoms. Findings across studies are variable, and many individuals show normal imaging.

​

This distinction is important. One might expect a clearer and more reproducible pattern of structural abnormalities if persistent withdrawal symptoms were primarily driven by fixed structural injury; however, available evidence has not demonstrated a consistent pattern of structural change, and standard imaging techniques have important limitations in detecting functional or network-level alterations.

​

In addition, standard clinical imaging does not capture many functional or network-level changes in brain activity—such as altered signaling, amplification, and regulation—which are increasingly recognized as important contributors to symptom generation.

​

While research tools such as functional MRI can demonstrate some of these changes at a group level, they are not currently used to explain or diagnose symptoms in individual patients.

 

​

Why Protracted Withdrawal Can Feel Like Injury​

​

When symptoms persist, fluctuate, or feel intense or unfamiliar, it is natural to interpret them as evidence of damage.

​

However, many features of protracted benzodiazepine withdrawal follow recognizable patterns, including variability over time, sensitivity to stress, shifting symptom patterns, and partial reversibility.

​

These patterns are more consistent with changes in system function than with fixed structural injury.

​

This does not mean symptoms are psychological or imagined. It means the nervous system is functioning differently, rather than showing evidence of ongoing structural damage.

​​

​

How Symptom Interpretation Shapes Recovery​

 

How symptoms are interpreted has real consequences. It shapes not only how symptoms are understood, but how patients respond to them—affecting fear, engagement, and expectations for recovery.

​

If symptoms are understood as permanent injury, fear often increases, symptoms may be monitored more closely, and recovery can feel uncertain or out of reach.

​

If symptoms are understood as dysregulation, the focus shifts toward stabilization—reducing stress on the system and supporting a gradual return toward regulation.

​

This perspective does not minimize symptoms. It places them within a biological framework consistent with current neuroscience while acknowledging uncertainty.

​

It can reduce catastrophic interpretations, support treatment engagement, and open the door to intervention.

For this reason, treatment often focuses on stabilization rather than attempting to “repair” a fixed injury.​

​

​

Clinical Patterns in Protracted Withdrawal​

 

In clinical practice, this pattern is commonly observed, even though it is not always well described in the literature. Patients often report symptoms that fluctuate over time, shift between systems, intensify with stress or physiological strain, and improve—at least partially—with stabilization.

​

These patterns are difficult to explain using a model of fixed structural injury. They are more consistent with a system in a dysregulated state, in which signal generation, amplification, and regulation remain altered.

Within this framework, symptoms can persist without clear evidence of structural injury, change in form and intensity, and improve gradually as system regulation stabilizes.

​

Once established, these patterns may appear self-reinforcing in clinical practice. Ongoing activation, amplification, stress responses, and symptom monitoring can increase overall system load, allowing symptoms to persist even after the original trigger has resolved.

​

This perspective helps explain not only why symptoms persist, but why they behave the way they do.

 

​

A Broader Neuroscience Perspective​

 

This perspective is not unique to benzodiazepine withdrawal. Across multiple areas of medicine, symptoms are increasingly understood as arising from changes in system function rather than from identifiable structural damage.

​

Examples include chronic pain, functional neurological disorders, post-viral conditions such as long COVID, and autonomic disorders.

​

These conditions illustrate a broader principle: symptoms can be real, severe, and persistent without requiring identifiable structural damage.

​

In this context, persistent symptoms are increasingly understood as reflecting changes in how signals are generated, amplified, predicted, and regulated across interacting systems.

​

Rather than being an isolated phenomenon, protracted benzodiazepine withdrawal can be understood as one example of a broader class of conditions involving dysregulated brain–body signaling.

 

​

Reframing Symptoms and Recovery​

 

Persistent symptoms after benzodiazepine withdrawal are not imagined, and they are not trivial. But they may not reflect what they initially appear to reflect.

​

In many cases, these symptoms reflect ongoing changes in how the nervous system generates, amplifies, and regulates signals—rather than clear evidence of structural injury.

​

This helps explain why symptoms can persist, fluctuate, and change over time—and why they can improve.

 

When symptoms are viewed as a fixed injury, the focus often shifts toward damage and limitation.

When understood as dysregulation, the focus shifts toward stabilization—reducing system load and supporting the nervous system’s capacity to recalibrate over time.

​

This does not minimize symptoms. It places them within a biologically grounded framework consistent with current neuroscience, while acknowledging uncertainty.

​

It also provides a way to understand recovery as a dynamic process—one that reflects changes in system function rather than repair of a fixed injury.

​

Recovery, in this context, is not the repair of damage—it is the gradual restoration of system stability and regulation.

​

​

Selected references:

​

Allison, C., & Pratt, J. A. (2003). Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacology & Therapeutics, 98(2), 171–195.

​

Ashton, H. (1991). Protracted withdrawal syndromes from benzodiazepines. Journal of Substance Abuse Treatment, 8(1–2), 19–28.

​

Ashton, H. (2002). Benzodiazepines: How they work and how to withdraw (The Ashton Manual).

​

Barrett, L. F., & Simmons, W. K. (2015). Interoceptive predictions in the brain. Nature Reviews Neuroscience, 16(7), 419–429.

​

Brett, J., & Murnion, B. (2015). Management of benzodiazepine misuse and dependence. Australian Prescriber, 38(5), 152–155.

​

Busto, U. E., Bremner, K. E., Knight, K., & Sellers, E. M. (2000). Long-term benzodiazepine therapy does not result in brain abnormalities. Journal of Clinical Psychopharmacology, 20(1), 2–6.

​

Dani, M., Dirksen, A., Taraborrelli, P., Torocastro, M., Panagopoulos, D., Sutton, R., & Lim, P. B. (2021). Autonomic dysfunction in long COVID: Rationale, physiology and management strategies. Clinical Medicine, 21(1), e63–e67.

​

Drane, D. L., Fani, N., Hallett, M., Khalsa, S. S., Perez, D. L., & Roberts, N. A. (2021). A framework for understanding the pathophysiology of functional neurological disorder. CNS Spectrums, 26(6), 555–561.

​

Feldman, M. J., Bliss-Moreau, E., & Lindquist, K. A. (2024). The neurobiology of interoception and affect. Trends in Cognitive Sciences, 28(7), 643–661.

​

Lader, M. (2011). Benzodiazepines revisited—will we ever learn? Addiction, 106(12), 2086–2109.

Logothetis, N. K. (2008). What we can do and what we cannot do with fMRI. Nature, 453(7197), 869-878.

 

McEwen, B. S. (2000). Allostasis and allostatic load: Implications for neuropsychopharmacology. Neuropsychopharmacology, 22(2), 108–124.

​

Pétursson, H. (1994). The benzodiazepine withdrawal syndrome. Addiction, 89(11), 1455–1459.

 

Seth, A. K., & Friston, K. J. (2016). Active interoceptive inference and the emotional brain. Philosophical Transactions of the Royal Society B: Biological Sciences, 371(1708).

 

Woolf, C. J. (2011). Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 152(3 Suppl), S2–S15.